Exicure Inc (XCUR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.07M
Last updated: Nov 17, 2026 at 10:55 AM ET
Exicure Inc (XCUR) Competitors
The companies most similar to Exicure are Ensysce Biosciences (ENSC), In8bio (INAB) and Soligenix (SNGX). By market cap, Exicure ranks 7th of the 13 companies on this page; Intensity Therapeutics, Inc. Common stock (INTS) is the largest at $10.17M.
Peer Comparison
XCUR's revenue growth of 928.0% is above the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Exicure (XCUR) | $7.07M | N/A | N/A | 0.0% | N/A | 928.0% | 0.00% |
| Ensysce Biosciences Inc (ENSC) | $8.14M | N/A | 1.2x | -280.5% | -260.6% | -15.1% | 0.00% |
| In8bio Inc (INAB) | $8.86M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Soligenix Inc. (SNGX) | $7.50M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Enveric Biosciences Inc (ENVB) | $6.78M | N/A | 0.2x | 0.0% | N/A | -7.3% | 0.00% |
| Theriva Biologics Inc. (TOVX) | $6.61M | N/A | 21.5x | 0.0% | -52.3% | 0.0% | 0.00% |
| CNS Pharmaceuticals Inc (CNSP) | $4.22M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Skye Bioscience, Inc. Common Stock (SKYE) | $4.83M | N/A | N/A | 0.0% | -3685.3% | 0.0% | 0.00% |
| GT Biopharma Inc (GTBP) | $7.67M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Imunon Inc (IMNN) | $4.08M | N/A | N/A | 0.0% | -131.5% | 0.0% | 0.00% |
| Intensity Therapeutics, Inc. Common stock (INTS) | $10.17M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Moleculin Biotech Inc (MBRX) | $8.02M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Senti Biosciences Inc (SNTI) | $5.38M | N/A | 57.2x | 0.0% | 1039.8% | -100.0% | 0.00% |
| Peer median | $7.14M | N/A | 11.4x | 0.0% | -131.5% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Exicure, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Ensysce Biosciences Inc (ENSC) | Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs. | ENSC competitors |
| In8bio Inc (INAB) | IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers... | INAB competitors |
| Soligenix Inc. (SNGX) | Soligenix, Inc., an advanced stage biopharmaceutical company, focuses on developing and marketing products to treat rare diseases in the United States. | SNGX competitors |
| Enveric Biosciences Inc (ENVB) | Enveric Biosciences, Inc., a pharmaceutical company, is dedicated to developing various cannabinoid drugs for the treatment of cancer. | ENVB competitors |
| Theriva Biologics Inc. (TOVX) | Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. | TOVX competitors |
| CNS Pharmaceuticals Inc (CNSP) | CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central... | CNSP competitors |
| Skye Bioscience, Inc. Common Stock (SKYE) | Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops... | SKYE competitors |
| GT Biopharma Inc (GTBP) | GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its... | GTBP competitors |
| Imunon Inc (IMNN) | Imunon Inc. is a clinical-stage biotechnology company at the forefront of developing innovative immune-mediated therapies targeting cancer and infectious... | IMNN competitors |
| Intensity Therapeutics, Inc. Common stock (INTS) | Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems. | INTS competitors |
| Moleculin Biotech Inc (MBRX) | Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant... | MBRX competitors |
| Senti Biosciences Inc (SNTI) | Senti Biosciences Inc (SNTI) is a leading biotechnology firm specializing in synthetic biology... | SNTI competitors |
Frequently Asked Questions About XCUR
Who are Exicure's main competitors?
The companies most similar to Exicure include Ensysce Biosciences (ENSC), In8bio (INAB), Soligenix (SNGX), Enveric Biosciences (ENVB) and Theriva Biologics (TOVX), listed from the closest match.
Who is Exicure's biggest competitor?
Intensity Therapeutics, Inc. Common stock (INTS) is the largest of the similar companies at $10.17M; Ensysce Biosciences (ENSC) is the closest match by business profile, size, sector and industry.
How does XCUR stock compare with its competitors?
XCUR's net margin is 0.0% against a peer median of 0.0%.
Which of Exicure's competitors pays a higher dividend?
Exicure pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Exicure bigger than its competitors?
No. Exicure is 7th by market cap among the 13 companies on this page; the largest is Intensity Therapeutics, Inc. Common stock (INTS) at $10.17M.
XCUR pages: Overview, Earnings, Financials, Competitors